Literature DB >> 29940120

Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase.

Nicole Blaquiere1, Georgette M Castanedo1, Jason D Burch1, Leonid M Berezhkovskiy1, Hans Brightbill1, Suzanne Brown1, Connie Chan1, Po-Chang Chiang1, James J Crawford1, Teresa Dong1, Peter Fan1, Jianwen Feng1, Nico Ghilardi1, Robert Godemann2, Emily Gogol1, Alice Grabbe2, Alison J Hole2, Baihua Hu3, Sarah G Hymowitz1, Moulay Hicham Alaoui Ismaili1, Hoa Le1, Patrick Lee1, Wyne Lee1, Xingyu Lin3, Ning Liu1, Paul A McEwan2, Brent McKenzie1, Hernani L Silvestre2, Eric Suto1, Swathi Sujatha-Bhaskar1, Guosheng Wu3, Lawren C Wu1, Yamin Zhang3, Zoe Zhong1, Steven T Staben1.   

Abstract

NF-κB-inducing kinase (NIK) is a protein kinase central to the noncanonical NF-κB pathway downstream from multiple TNF receptor family members, including BAFF, which has been associated with B cell survival and maturation, dendritic cell activation, secondary lymphoid organ development, and bone metabolism. We report herein the discovery of lead chemical series of NIK inhibitors that were identified through a scaffold-hopping strategy using structure-based design. Electronic and steric properties of lead compounds were modified to address glutathione conjugation and amide hydrolysis. These highly potent compounds exhibited selective inhibition of LTβR-dependent p52 translocation and transcription of NF-κB2 related genes. Compound 4f is shown to have a favorable pharmacokinetic profile across species and to inhibit BAFF-induced B cell survival in vitro and reduce splenic marginal zone B cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29940120     DOI: 10.1021/acs.jmedchem.8b00678

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells.

Authors:  Peilu Song; Fan Zhao; Dahong Li; Jiqiang Qu; Miao Yao; Yuan Su; Hanxun Wang; Miaomiao Zhou; Yujie Wang; Yinli Gao; Feng Li; Dongmei Zhao; Fengjiao Zhang; Yu Rao; Mingyu Xia; Haitao Li; Jian Wang; Maosheng Cheng
Journal:  Acta Pharm Sin B       Date:  2022-03-04       Impact factor: 14.903

2.  Pathogenic signaling in multiple myeloma.

Authors:  Arnold Bolomsky; Ryan M Young
Journal:  Semin Oncol       Date:  2022-01-20       Impact factor: 5.385

3.  NF-κB-inducing kinase (NIK) is activated in pancreatic β-cells but does not contribute to the development of diabetes.

Authors:  Peng Xiao; Tatiana Takiishi; Natalia Moretti Violato; Giada Licata; Francesco Dotta; Guido Sebastiani; Lorella Marselli; Sumeet Pal Singh; Mozes Sze; Geert Van Loo; Emmanuel Dejardin; Esteban Nicolas Gurzov; Alessandra Kupper Cardozo
Journal:  Cell Death Dis       Date:  2022-05-19       Impact factor: 9.685

Review 4.  Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer.

Authors:  Kathryn M Pflug; Raquel Sitcheran
Journal:  Int J Mol Sci       Date:  2020-11-11       Impact factor: 5.923

5.  Electrochemical [4 + 1] Tandem sp3(C-H) Double Amination for the Direct Synthesis of 3-Acyl-Functionalized Imidazo[1,5-a]pyridines.

Authors:  Qiang Wang; Xia Yao; Xian-Jing Xu; Shuai Zhang; Lei Ren
Journal:  ACS Omega       Date:  2022-01-27

6.  The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-κB signaling.

Authors:  Joshua K Tay; Chunfang Zhu; June Ho Shin; Shirley X Zhu; Sushama Varma; Joseph W Foley; Sujay Vennam; Yim Ling Yip; Chuan Keng Goh; De Yun Wang; Kwok Seng Loh; Sai Wah Tsao; Quynh-Thu Le; John B Sunwoo; Robert B West
Journal:  Sci Adv       Date:  2022-04-08       Impact factor: 14.136

Review 7.  The Therapeutic Potential of Targeting NIK in B Cell Malignancies.

Authors:  Marco V Haselager; Eric Eldering
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

Review 8.  Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases.

Authors:  Jing Cheng; Xuexin Feng; Zhiqiang Li; Feilong Zhou; Jin-Ming Yang; Yujun Zhao
Journal:  RSC Med Chem       Date:  2021-01-22

Review 9.  Inhibitory-κB Kinase (IKK) α and Nuclear Factor-κB (NFκB)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets.

Authors:  Andrew Paul; Joanne Edwards; Christopher Pepper; Simon Mackay
Journal:  Cells       Date:  2018-10-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.